Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anivamersen
- Development stage
- Phase 1
- Lead developer
- Allergan
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
Anivamersen is a synthetic antisense oligonucleotide developed as part of the REG1 anticoagulation system, which also includes pegnivacogin. Anivamersen acts as a reversal agent for pegnivacogin, a nucleotide aptamer that inhibits coagulation factor IXa. By binding to pegnivacogin through Watson–Crick base pairing, anivamersen neutralizes its anticoagulant effect within minutes after intravenous administration. The resulting complex is biologically inert and cleared via nuclease-mediated degradation. The REG1 system was investigated primarily for use in patients undergoing percutaneous coronary intervention (PCI) and for the treatment of acute coronary syndrome and venous thrombosis[6][7][8]. Development was discontinued after phase 3 trials.
- Other names
- anivamersen sodium
02
Targets
Coagulation Factor IXa
Beyond the preview
Go deeper on Anivamersen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anivamersen.